-$2.03 Earnings Per Share Expected for Sage Therapeutics, Inc. (NASDAQ:SAGE) This Quarter

Equities analysts expect that Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Rating) will post ($2.03) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Eleven analysts have issued estimates for Sage Therapeutics’ earnings. The lowest EPS estimate is ($2.51) and the highest is ($0.78). Sage Therapeutics posted earnings per share of ($1.83) during the same quarter last year, which suggests a negative year over year growth rate of 10.9%. The business is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Sage Therapeutics will report full-year earnings of ($8.66) per share for the current financial year, with EPS estimates ranging from ($10.17) to ($7.55). For the next year, analysts forecast that the company will report earnings of ($7.33) per share, with EPS estimates ranging from ($9.97) to ($4.09). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that that provide coverage for Sage Therapeutics.

Sage Therapeutics (NASDAQ:SAGE – Get Rating) last released its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.06) by ($0.01). The firm had revenue of $1.58 million for the quarter, compared to analysts’ expectations of $3.23 million. Sage Therapeutics had a negative net margin of 7,676.91% and a negative return on equity of 27.23%. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter last year, the firm earned ($1.64) earnings per share.

Several research analysts recently issued reports on the stock. The Goldman Sachs Group cut their target price on shares of Sage Therapeutics to $96.00 and set a “buy” rating for the company in a research report on Thursday, February 17th. Berenberg Bank started coverage on shares of Sage Therapeutics in a research note on Thursday, March 31st. They issued a “hold” rating and a $37.00 price target for the company. Morgan Stanley lowered their price target on shares of Sage Therapeutics from $61.00 to $57.00 and set an “equal weight” rating for the company in a research note on Thursday, March 10th. StockNews.com started coverage on shares of Sage Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating for the company. Finally, Mizuho lowered their price target on shares of Sage Therapeutics from $41.00 to $37.00 in a research note on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $62.95.

NASDAQ:SAGE traded up $1.19 during midday trading on Friday, hitting $30.71. The company had a trading volume of 653,428 shares, compared to its average volume of 638,893. Sage Therapeutics has a 52-week low of $27.36 and a 52-week high of $79.45. The stock’s fifty day moving average price is $33.35 and its 200-day moving average price is $37.87. The company has a market capitalization of $1.81 billion, a PE ratio of -3.73 and a beta of 1.57.

In related news, Director George Golumbeski acquired 8,000 shares of the stock in a transaction that occurred on Thursday, May 5th. The shares were bought at an average price of $31.45 per share, for a total transaction of $251,600.00. Following the completion of the transaction, the director now directly owns 8,000 shares in the company, valued at $251,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.70% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amundi Pioneer Asset Management Inc. raised its position in shares of Sage Therapeutics by 40.7% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock valued at $21,704,000 after purchasing an additional 39,447 shares during the period. OLD Mission Capital LLC purchased a new position in Sage Therapeutics during the third quarter valued at $554,000. Morgan Stanley grew its stake in Sage Therapeutics by 133.7% during the second quarter. Morgan Stanley now owns 577,716 shares of the biopharmaceutical company’s stock valued at $32,820,000 after acquiring an additional 330,541 shares in the last quarter. Victory Capital Management Inc. grew its stake in Sage Therapeutics by 35.6% during the third quarter. Victory Capital Management Inc. now owns 9,245 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 2,426 shares in the last quarter. Finally, Van ECK Associates Corp grew its stake in Sage Therapeutics by 59.3% during the third quarter. Van ECK Associates Corp now owns 1,203 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 448 shares in the last quarter. Institutional investors and hedge funds own 84.40% of the company’s stock.

Sage Therapeutics Company Profile (Get Rating)

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.

Read More